Patents Assigned to Osmotica Kereskedelmi es Szolgaltato Kft
-
Patent number: 11717483Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: April 5, 2021Date of Patent: August 8, 2023Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
-
Patent number: 11679088Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: July 8, 2021Date of Patent: June 20, 2023Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Publication number: 20210401785Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: July 8, 2021Publication date: December 30, 2021Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20210283062Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: April 5, 2021Publication date: September 16, 2021Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
-
Patent number: 11090281Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: February 24, 2020Date of Patent: August 17, 2021Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 10987312Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: December 31, 2019Date of Patent: April 27, 2021Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
-
Patent number: 10987328Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: April 10, 2019Date of Patent: April 27, 2021Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 10695336Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: February 6, 2019Date of Patent: June 30, 2020Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Publication number: 20200188341Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: February 24, 2020Publication date: June 18, 2020Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20200129439Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: December 31, 2019Publication date: April 30, 2020Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
-
Patent number: 10610505Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: December 6, 2018Date of Patent: April 7, 2020Assignee: Osmotica Kereskedelmi ES Szolgaltato KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 10532031Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: November 2, 2018Date of Patent: January 14, 2020Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
-
Patent number: 10471031Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: February 8, 2019Date of Patent: November 12, 2019Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Publication number: 20190255005Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: April 10, 2019Publication date: August 22, 2019Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20190167618Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: February 8, 2019Publication date: June 6, 2019Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20190167654Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: ApplicationFiled: February 6, 2019Publication date: June 6, 2019Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: HERNAN D. BENEDETTI, CRISTIAN R. FRANCO, GUIDO S. BIGATTI, JOAQUINA FAOUR, ANA C. PASTINI
-
Patent number: 10300032Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: GrantFiled: August 18, 2017Date of Patent: May 28, 2019Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Patent number: 10265308Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: July 21, 2017Date of Patent: April 23, 2019Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Publication number: 20190111013Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: December 6, 2018Publication date: April 18, 2019Applicant: Osmotica Kereskedelmi ES Szolgaltato KFTInventors: Glenn A. MEYER, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
-
Publication number: 20190070121Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: November 2, 2018Publication date: March 7, 2019Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT